XORTX Therapeutics (TSXV:XRTX) Total Assets : C$5.22 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Total Assets?

XORTX Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was C$5.22 Mil.

During the past 12 months, XORTX Therapeutics's average Total Assets Growth Rate was -1.30% per year. During the past 3 years, the average Total Assets Growth Rate was 8.40% per year. During the past 5 years, the average Total Assets Growth Rate was 26.50% per year.

During the past 9 years, XORTX Therapeutics's highest 3-Year average Total Assets Growth Rate was 652.20%. The lowest was 8.40%. And the median was 55.15%.

Total Assets is connected with ROA %. XORTX Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -53.93%. Total Assets is also linked to Revenue through Asset Turnover. XORTX Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

XORTX Therapeutics Total Assets Historical Data

The historical data trend for XORTX Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Total Assets Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

1.10

2.30

22.25

16.81

7.34

XORTX Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															8.99	7.34	8.19	6.58	5.22

XORTX Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

XORTX Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	6.228	+	1.108
	=	7.34

XORTX Therapeutics's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	2.891	+	2.326
	=	5.22

XORTX Therapeutics (TSXV:XRTX) Total Assets Explanation

Total Assets is connected with ROA %.

XORTX Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-3.18	/	( (6.577	+	5.215)	/ 2 )
	=	-3.18	/	5.896
	=	-53.93 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

XORTX Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (6.577	+	5.215)	/ 2 )
=	0	/	5.896
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

XORTX Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Executives

Allen Warren Davidoff	Director, Senior Officer
Amar Deep Keshri	Senior Officer
William Bruce Rowlands	Director
James Neville Fairbairn	Senior Officer
Allan William Williams	Director
Paul Joseph Van Damme	Director